Page last updated: 2024-11-09

1-butyl-3-methylimidazolium chloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-butyl-3-methylimidazolium chloride: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2734161
CHEMBL ID3183408
SCHEMBL ID36718
SCHEMBL ID3859328
MeSH IDM0488006

Synonyms (51)

Synonym
AKOS015833153
3-butyl-1-methyl-1h-imidazol-3-ium chloride (ionic liquid)
79917-90-1
1-butyl-3-methylimidazolium chloride
1-butyl-3-methylimidazolium chloride, >=98.0% (hplc)
B2194
tox21_303611
dtxcid4011461
cas-79917-90-1
NCGC00257359-01
dtxsid6031461 ,
tox21_201690
NCGC00259239-01
FT-0608140
(bmim)cl
unii-41ps77334a
1h-imidazolium, 3-butyl-1-methyl-, chloride (1:1)
butylmethylimidazolium chloride
basionic st-70
3-butyl-1-methylimidazolium chloride
41ps77334a ,
butylmethylimidazolium chloride [mi]
1-n-butyl-3-methylimidazolium chloride
3-butyl-1-methyl-1h-imidazol-3-ium chloride
AKOS015901576
bmimcl
FHDQNOXQSTVAIC-UHFFFAOYSA-M
1-butyl-3-methylimi-dazolium chloride
1-butyl-3-methyl imidazolium chloride
1-methyl-3-butyl imidazolium chloride
SCHEMBL36718
SCHEMBL3859328
1-butyl-3-methyl-1h-imidazol-3-ium chloride
Q-102658
AC-30201
CHEMBL3183408
mfcd03095425
1-butyl-3-methylimidazolium chloride, >=99.0% (hplc)
1-butyl-3-methylimidazolium chloride, >=99%
SY023278
Q5772857
[bmim]cl
CS-W017474
1-butyl-3-methylimidazol-3-ium;chloride
AS-17508
AC1310
A864791
3-butyl-1-methyl-1h-imidazol-3-iumchloride
1-butyl-3-methylimidazolium chloride, puriss
1-butyl-3-methylimidazolium chloride [bmim]cl
1-butyl-3-methylimidazolium chloride (hplc)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Although considered as "green" solvents, the toxic effects of ionic liquids (ILs) on organisms have been widely investigated in recent years."( The genotoxic and cytotoxic effects of 1-butyl-3-methylimidazolium chloride in soil on Vicia faba seedlings.
Liu, T; Wang, J; Xie, H; Zhu, L, 2015
)
0.69
"This study deals with the toxic effect of ionic liquid, 1-butyl-3-methylimidazolium bromide (BMImBr) on guppy fish, Poecilia reticulata."( Toxicity study of ionic liquid, 1-butyl-3-methylimidazolium bromide on guppy fish, Poecilia reticulata and its biodegradation by soil bacterium Rhodococcus hoagii VRT1.
Kodam, KM; Thamke, VR, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" Systemic bioavailability was determined to be 62."( The effects of dose and route on the toxicokinetics and disposition of 1-butyl-3-methylimidazolium chloride in male F-344 rats and female B6C3F1 mice.
Knudsen, GA; Kuester, RK; Sipes, IG, 2008
)
0.58
" This reduction of freely dissolved concentration gave rise to remarkable reduction of bioavailability and toxicity of the two ILs."( Sorption to dissolved humic acid and its impacts on the toxicity of imidazolium based ionic liquids.
Cai, XQ; Jiang, GB; Jiang, WW; Liu, JF; Luo, WR; Zhang, Z, 2011
)
0.37
" These results evidenced the different influence of the IL structure and operating conditions on the solubility and absorption rate of CO2, illustrating the importance of considering both thermodynamic and kinetic aspects to select adequate ILs for CO2 absorption."( Anion effects on kinetics and thermodynamics of CO2 absorption in ionic liquids.
Abrusci, C; Bedia, J; Gonzalez-Miquel, M; Palomar, J; Rodriguez, F, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
"From gestation days (GD) 6-16, mated CD-1 mice were orally dosed with one of the following: 1,000, 2,000, or 3,000 mg/kg/day [C(2)mim]Cl; 113, 169, or 225 mg/kg/day [C(4)mim]Cl; 50, 75, or 100 mg/kg/day [C(10)mim]Cl; or the vehicle only."( A comparison of the effects of prenatal exposure of CD-1 mice to three imidazolium-based ionic liquids.
Bailey, MM; Beaird, J; Di Bona, KR; Henson, MB; Hood, RD; Hough, WL; Jernigan, PL; Lockhard, JE; Lovich, AN; Rasco, JF; Rogers, RD; Sherrill, J; Sturdivant, J; Swatloski, RP, 2010
)
0.36
"Fetal weight was significantly decreased in the two highest dosage groups exposed to [C(4)mim]Cl and [C(10)mim]Cl in comparison with their controls, but the [C(2)mim]Cl treated groups were not affected."( A comparison of the effects of prenatal exposure of CD-1 mice to three imidazolium-based ionic liquids.
Bailey, MM; Beaird, J; Di Bona, KR; Henson, MB; Hood, RD; Hough, WL; Jernigan, PL; Lockhard, JE; Lovich, AN; Rasco, JF; Rogers, RD; Sherrill, J; Sturdivant, J; Swatloski, RP, 2010
)
0.36
" The effects of catalyst dosage (mole ratio of catalyst to glucose units in the feedstock) and reaction temperature on HMF yields were investigated to obtain optimal process conditions."( Catalytic hydrolysis of lignocellulosic biomass into 5-hydroxymethylfurfural in ionic liquid.
Wang, P; Wang, S; Yu, H; Zhan, S, 2011
)
0.37
" Various reaction parameters such as reaction time, reaction temperature, solvent and catalyst dosage were investigated in detail."( Efficient conversion of cellulose into biofuel precursor 5-hydroxymethylfurfural in dimethyl sulfoxide-ionic liquid mixtures.
Fang, Z; Liu, B; Wang, Y; Xiao, S; Zhang, Z, 2014
)
0.4
" Also, it was found that the dye can be higher adsorbed on the beads surface by increasing the sorbent dosage and pH of solution, while the optimum dosage and pH were obtained 3 mg/L and 11, respectively."( Novel 1-butyl-3-methylimidazolium bromide impregnated chitosan hydrogel beads nanostructure as an efficient nanobio-adsorbent for cationic dye removal: Kinetic study.
Alizadeh, M; Ayati, A; Karimi, F; Karimi-Maleh, H; Orooji, Y; Ranjbari, S; Rouhi, J; Salmanpour, S; Sen, F; Sillanpää, M; Tanhaei, B, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency74.96320.002541.796015,848.9004AID1347395
progesterone receptorHomo sapiens (human)Potency27.30600.000417.946075.1148AID1346784
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency33.07530.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.61130.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency31.50180.000229.305416,493.5996AID743069; AID743075; AID743079
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.86350.000323.4451159.6830AID743065
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1271200Cytotoxicity against human 3215LS cells after 24 hrs by MTT assay2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Cytotoxic Activity of Salicylic Acid-Containing Drug Models with Ionic and Covalent Binding.
AID1271201Cytotoxicity against human Caco2 cells after 24 hrs by MTT assay2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Cytotoxic Activity of Salicylic Acid-Containing Drug Models with Ionic and Covalent Binding.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (215)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's30 (13.95)29.6817
2010's173 (80.47)24.3611
2020's12 (5.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.51 (24.57)
Research Supply Index5.38 (2.92)
Research Growth Index5.10 (4.65)
Search Engine Demand Index58.93 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.46%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other216 (99.54%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]